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With a prevalence of 5.8 million in the United States alone, heart failure (HF) is a common syndrome associated with
substantial morbidity, mortality, and healthcare expenditures. Close to 1 million HF hospitalizations occur annually in
the United States, with the majority of these resulting from worsening congestion in patients previously diagnosed
with HF. An estimated $37.2 billion is spent each year on HF in the United States. These statistics emphasize the
need to develop and implement more effective strategies to assess, monitor, and treat HF. It has also become in-
creasingly apparent that interventions geared toward identifying and monitoring subclinical congestion would be of
value in the home management of chronic HF. Earlier identification and treatment of congestion together with im-
proved care coordination, management of comorbid conditions, and enhanced patient self-management may help to
prevent hospitalizations in patients with chronic HF. Such home monitoring extends from the promotion of self-care
and home visitations to telemedicine and remote monitoring of external or implantable devices. This paper discusses
the challenges in monitoring patients with HF, reviews clinical trials testing different monitoring strategies in HF, and
highlights ongoing investigations into the optimal approaches to home monitoring for HF. (J Am Coll Cardiol 2012;
59:97–104) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.044Heart failure (HF) is a common clinical syndrome with
frequent exacerbations requiring hospitalization. HF is chal-
lenging to manage because of the older patient population,
often subtle onset of decompensation, and the complexities of
the required lifestyle changes, medication regimen, laboratory
monitoring, and interactions with comorbid conditions. Cer-
tain multidisciplinary HF disease management programs have
been successful at reducing all-cause hospitalization rates (1,2).
However, not all patients can participate in such programs
because of geographic barriers, socioeconomic constraints, or
other obstacles. Interventions have therefore evolved to better
monitor the patient with HF at home. These interventions
range from increasing self-care and structured telephone sup-
port to telemonitoring and remote monitoring of implantable
devices. How these advances in monitoring will ultimately
affect HF disease burden, progression, and health care expen-
ditures is of great interest and under active investigation.
Challenges in HF Management
The difficulty in managing HF is manifest not only by a
high rate of HF hospitalizations, currently estimated at
approximately 1 million annually in the United States (3),
but also by a 30-day readmission rate of 27%, the highest
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(4). Acute in-hospital care is responsible for up to 70% of
the annual cost of HF in the United States and other
developed countries (5). Given the aging population and
growing economic burden, improved management of the
patient with HF at home and prevention of hospital
admissions have become national priorities. Rehospitaliza-
tion rates for HF are now the target of publicly reported
performance measures, national improvement initiatives,
and government incentives (6).
Standard management of the ambulatory HF patient
involves office-based follow-up 2 to 12 times a year, with
physical examinations supplemented by laboratory tests and
echocardiograms as needed. Patients are instructed to mon-
itor their weight and symptoms. Therapy provided in this
manner, however, is often adjusted in response to new
complaints brought by the patient. Although routinely used
in the outpatient setting to detect HF decompensation,
there are limitations to the monitoring of symptoms, phys-
ical examination signs, and daily weight. Better strategies
geared toward identifying subclinical congestion and antic-
ipating severe episodes of decompensation would be of
value. Instead of being episodic and reactive, care could then
become proactive through continual home observation,
education, and assistance to prevent deterioration (Fig. 1).
Self-Care and Self-Management
The American Heart Association defines self-care as the
decision-making process patients use to maintain physio-
logical stability (7). Self-care includes multiple components,
such as adhering to medications, following diet and
98 Bui and Fonarow JACC Vol. 59, No. 2, 2012
HF Home Monitoring January 10, 2012:97–104exercise recommendations, and
actively monitoring for congestion.
Self-management extends this
concept to the self-adjustment
of the treatment regimen. Self-
management is therefore a com-
plex process: patients have to rec-
ognize a change in themselves
(e.g., increasing edema), evaluate
the symptom, decide to take ac-
tion, implement a treatment
strategy (e.g., taking an extra di-
uretic dose), and evaluate the re-
sponse to therapy (7). Self-care
and self-management behaviors are ultimately the respon-
sibilities of the patient, even if they are frequently seen in
the office or telephoned at home.
However, there are multiple challenges with self-care for
the patient. Although checking daily weight is an important
part of HF self-management (8), fewer than one-half of
patients with HF weigh themselves daily, even among those
recently discharged for an HF exacerbation (9). But even if
they did so, an increase of 2 kg over 24 to 72 h has only
a 9% sensitivity for detecting clinical deterioration (10).
Furthermore, patients may delay seeking care for HF
symptoms for days or fail to bring new symptoms to the
attention of their providers when they are seen (11).
Multiple comorbidities often compound the challenges in
self-care. Other conditions may require additional, possibly
conflicting, medications, and it is common for patients with
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Figure 1 Usual Care Versus Hemodynamic Monitoring and Guid
Comparison of monitoring, assessments, visits, and the approach to therapy with
guided home care for patients with heart failure (HF). ED  emergency departmenHF to take 9 to 12 pills per day, without a good under-
standing of their treatment regimen (12). Symptom moni-
toring may also be more uncertain: patients with chronic
obstructive pulmonary disease often cannot distinguish HF
versus their lung disease as the cause of shortness of breath.
Patients with diabetes may have fewer symptoms and more
difficulty interpreting them (7). Patients with HF may also
have lower health literacy levels as well as cognitive impair-
ment. In a study of Medicare enrollees, 27% to 44% were
found to have marginal or inadequate health literacy (13).
Additional factors such as social isolation or concurrent
depression also hamper self-care. Taken together, these
obstacles frequently prevent HF patients from fully imple-
menting self-management through medication taking, di-
etary and lifestyle adherence, symptom monitoring, and
decision making.
Although self-care for HF has been strongly advocated,
this approach has not been well tested in prospective
randomized clinical trials. The HART (Heart Failure Ad-
herence and Retention Trial) was a multiple-hospital, ran-
domized controlled trial testing the value of self-
management counseling in 902 patients with mild to
moderate HF (14). This study found no impact of this
intervention on reducing death or HF hospitalizations.
Although there is a paucity of evidence that patients with
HF benefit from self-management counseling on important
clinical endpoints, it remains possible that if self-care were
coupled with other interventions such as technology-
assisted remote monitoring, benefits would emerge.
ome Care for Patients With HF
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Guidelines by both European and U.S. scientific societies
have recommended a multidisciplinary approach to HF
(15,16). Rich et al. (17) explored this intervention, using an
experienced cardiovascular research nurse to provide HF
education, a dietician to provide nutritional assessment and
guidance, social service personnel to facilitate discharge
planning, a geriatric cardiologist to review and simplify the
medications, and a study team to provide intensive
follow-up with home care, individualized home visits, and
telephone contact. This program reduced rehospitalization
rates by 44%, with improvement in quality of life scores and
a reduction in overall costs of care (Online Appendix). A
subsequent meta-analysis has found that multidisciplinary
teams reduce mortality by 25%, HF hospitalizations by
26%, and all-cause hospitalizations by 19% (18). Multidis-
ciplinary disease management programs, however, have
been unable to reach a wide spectrum of patients with HF
because of the limited resources of healthcare systems to
provide such intensive services and the limited resources of
patients to actively participate (19).
Structured Telephone Support
One adaptation of the multidisciplinary disease manage-
ment team model has been to use telephone calls. Informa-
tion about the patient’s condition would be gathered
through a structured telephone conversation, and patients
would be directed to follow up with their physician if there
was evidence for deterioration. Structured telephone sup-
port can help with monitoring, self-care management, or
both. Results, however, have been equivocal. Weinberger et
al. (20) focused on 1,396 general medicine patients and
found that a nurse-led telephone intervention, coupled with
comprehensive discharge planning and primary-care physi-
cian follow-up within 7 days of discharge, led to an increase
in hospitalization rates and more days of rehospitalization,
despite the increase in contact (Online Appendix). Con-
versely, Riegel et al. (21) were able to demonstrate that a
program of telephone contact with a computer decision
support system reduced hospitalization rates by 47.8%, with
lower inpatient costs and no evidence for cost shifting to the
outpatient side.
Meta-analyses of structured telephone support programs
suggest that telephone support may reduce HF rehospital-
ization by about 25% but has no significant impact on either
all-cause readmission rates or all-cause mortality (18,19).
The benefit of structured telephone support on HF read-
missions may be attributable in part to appropriate nurse
triage to immediate intervention in the face of clinical
deterioration. However, increased contact may also lead to
false alarms and pre-emptive admissions. Its true benefit
may be in shortening length of stay, as patients are admitted
earlier and can be discharged earlier if a high level of
monitoring is available at home (22). pTelemonitoring or Remote Monitoring
With advances in information communication technology,
monitoring can go beyond just telephone calls requesting
patient information. Telemonitoring involves the transfer of
physiological data such as blood pressure, weight, electro-
cardiographic signals, or oxygen saturation (Table 1)
through technology such as telephone lines, broadband,
satellite, or wireless networks. Similar to structured tele-
phone support, this strategy may lift some of the burden of
geographic or funding barriers limiting in-home visits (22).
By incorporating more data, telemonitoring also promises to
detect HF deterioration earlier, allowing for more prompt
and effective intervention. Two recent meta-analyses have
suggested that telemonitoring in ambulatory HF patients
can improve mortality by 17% to 47% during 6 to 12
months of follow-up and reduce hospitalizations by 7% to
48% (19,23). However, 2 large subsequent randomized
controlled trials suggest caution before widely using telem-
onitoring. In the TELE-HF (Telemonitoring to Improve
Heart Failure Outcomes) study, a telephone-based interac-
tive voice-response system that obtained symptom and
weight information provided no significant benefit over
usual care in terms of all-cause rehospitalization rates or
Potential Measurements for HF MonitoringTable 1 Potential Measurements for HF Monitoring
Patient-reported data
Signs and symptoms of congestion
Signs: Jugular venous distension, peripheral edema, pulmonary congestion/
rales, pleural effusions, S3 gallop
Symptoms: Dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea,
























Intrathoracic impedanceBNP  B-type natriuretic peptide; INR  international normalized ratio; NT-proBNP  N-terminal
ro–B-type natriuretic peptide; RV  right ventricular.
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(Telemedical Interventional Monitoring in Heart Failure)
study was not able to demonstrate a significant impact of
telemonitoring on HF-related rehospitalization rates or
mortality (25).
The negative findings of TELE-HF and TIM-HF high-
light the complexity of home monitoring interventions. In
contrast to more successful implementations of telemoni-
toring (26), TELE-HF relied on patient-initiated commu-
nication: patients had to use a toll-free telephone system in
which an automated voice asked a series of questions to
which they had to respond by using a keypad. Fourteen
percent of patients assigned to the telemonitoring arm never
used the automated call-in system, and only 55% were still
regularly using the system by the end of the study period
(24). Also, nurses in TELE-HF were not empowered to
change the medication regimen without physician consul-
tation, thus adding a layer of communication and delay.
Described by Desai and Stevenson as the “Circle of Home
Management of HF” (27), HF home management involves
multiple components of which monitoring is only one
factor. There also needs to be timely transmission of data,
receipt of the information by the appropriate staff who can
analyze and act on it, a feedback loop to the patient with
directions, and sufficient patient empowerment to under-
stand and implement the instructions. Also, although te-
lemonitoring promises to reduce the need for in-person
follow-up, it may actually increase the workload involved. In
the TELE-HF study, although there were only 25 patients
per site on average, there were 884 incidents per site
requiring responses.
Mobile phone–based remote monitoring systems along
with application-based support of HF patient education and
disease management could be relatively inexpensive and
convenient tools to improve HF home management. Mo-
bile phones are now widely available and have considerable
computational power, while being relatively inexpensive
compared with dedicated remote monitoring hardware.
These systems are also portable, enabling patients to be
monitored anywhere with mobile phone reception. Initial
studies have shown the potential of this approach in HF
home management (28), but further studies are needed. The
U.S. Agency for Healthcare Research and Quality has
recently provided substantial funding to support research
into the use of wireless and telephone care management to
reduce HF readmissions (29).
Implantable Devices
Because of the potential unreliability of patient-reported
or patient-collected data, attention has turned to im-
plantable devices that would automatically record data.
Because conventional means of detecting changes in fluid
status such as weight and symptom monitoring do not
provide sufficient warning, additional metrics might also
prove useful (Table 1). These implantable devices can takethe form of permanent pacemakers (PPM), implantable
cardioverter-defibrillators (ICD), or cardiac resynchroniza-
tion therapy devices that have been placed for other indi-
cations. Or, they can be specially designed implantable
hemodynamic sensors and monitors that can measure such
parameters as intracardiac pressures.
PPMs and ICDs. When PPM, ICD, and cardiac resyn-
chronization therapy devices are placed in patients with HF,
it would make sense to use their potential capabilities to
further evaluate the patient. Remote monitoring of these
devices generally involves the transmission of recorded data
through an external transmitter to the manufacturer’s cen-
tral database. Information is transferred on a regular basis,
and alerts are forwarded to the physician (30). Some
routinely monitored parameters may reflect a patient’s
clinical status and predict impending cardiac decompensa-
tion. For instance, atrial tachyarrhythmias (31), decreased
heart rate variability (a measure of autonomic nervous tone)
(32), and decreased patient activity level (as measured by
integrated accelerometers) (32) can all predict clinical de-
compensation. Furthermore, an increase in the number of
both appropriate and inappropriate shocks is associated with
increased risk of HF hospitalization and mortality (33).
Another measure provided by some of these devices is
intrathoracic impedance, which is the impedance measured
between the right ventricular lead tip and the generator. An
increase in pulmonary vascular congestion is reflected by
decreased impedance, which can be recorded and reported
by the device before symptom development (34). Although
optimal lead configurations and thresholds are still under
consideration, one such algorithm for impedance monitor-
ing has a sensitivity of 76% in predicting clinical decom-
pensation compared with 23% using weight change (Online
Appendix) (35). By combining intrathoracic impedance
measurements with other predictors, including atrial
fibrillation episodes, patient activity level, and heart rate
variability, Whellan et al. (36) were able to identify those
with more than a 5-fold risk for HF decompensation and
hospitalization.
Given these potential advantages, remote monitoring of
implantable devices has been endorsed by recent expert
consensus (37). Remote monitoring of PPM and ICD data
may allow for the more timely recognition of serious
arrhythmias, device problems, or worsening HF. With daily
data transmissions, the number of in-home follow-up or
clinic visits could be reduced without compromising safety,
while also saving patient, staff, and physician time. Trials of
PPM and ICD remote monitoring have found a reduction
in time until event diagnosis and time from event to clinical
decision (Online Appendix) (38–40), but the effects of this
monitoring on outcomes such as hospitalizations and mor-
tality are not yet available.
Implantable hemodynamic monitors. Elevations in left
ventricular filling pressures and pulmonary artery pressures
are closely correlated with clinical congestion, functional
limitation, and prognosis in patients with HF (41). These
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days to weeks before the onset of symptoms that typically
trigger hospital admission (41–43). Thus, ambulatory he-
modynamic monitoring could provide an early warning of
potential decompensation as well as facilitate the day-to-day
management of patients with HF by allowing for the
titration of medications on the basis of reliable physiological
data. Several systems are therefore currently under develop-
ment that measure pressures directly in the right ventricle
(RV), left atrium, and pulmonary artery.
The RV pressure sensor system is similar to a pacemaker
generator with a modified unipolar pacemaker lead (Chron-
icle, Medtronic, Minneapolis, Minnesota). Information in-
cludes continuous heart rate, body temperature, and hemo-
dynamics such RV systolic and diastolic pressures and
ePAD (RV pressure at maximal RV dP/dT), which corre-
lates with pulmonary artery diastolic pressures and thus
approximates left-sided filling pressures (44). Evaluation of
this device in the COMPASS-HF (Chronicle Offers Man-
agement to Patients with Advanced Signs and Symptoms of
Heart Failure) trial (46) in patients with New York Heart
Association (NYHA) functional class III and IV HF,
however, did not find a significant difference in HF events
(e.g., hospitalizations, emergency or urgent care visits re-
quiring intravenous therapy) between the intervention and
control groups (Online Appendix). It is possible that the
study was underpowered, that the event rate was lower than
expected in the control group, that the intervention group
did not have medications titrated aggressively enough, or
that the standard of care in the control group, consisting of
nearly weekly telephone contact, provided insufficient effect
contrast. Subsequent analysis of the COMPASS-HF data-
base found that HF patients with persistently high filling
pressures were at higher risk of hospitalization, suggesting it
may be more effective to use implantable hemodynamic
monitoring data to adjust medications with the goal of
reducing high filling pressures, irrespective of symptoms or
weight (46).
A device to directly measure left atrial pressure has also
been developed (HeartPOD, St. Jude Medical, Minneapo-
lis, Minnesota). This device has a sensor lead placed
intra-atrially through a transseptal puncture, which is then
linked to a coil antenna placed subpectorally. Evaluation of
this device among patients with NYHA functional class III
and IV HF in the observational HOMEOSTASIS (Hemo-
dynamically Guided Home Self-Therapy in Severe Heart
Failure Patients) study (43) found that those in the inter-
vention group had a lower risk of acute decompensation or
death (hazard ratio: 0.16 [95% confidence interval: 0.04 to
0.68]) (Online Appendix). Benefits may have been gained
by the more aggressive titration of medications, as guided by
left atrial pressure. This particular intervention notably
included a “patient advisor module” that displayed the
measured left atrial pressure and reminded patients of which
medications were due based on the readings. This device
therefore has the potential to support patient self-management by allowing for participation and control in
patients’ day-to-day HF care (30).
A pulmonary artery sensor (CardioMEMS Heart Sensor,
CardioMEMS, Inc., Atlanta, Georgia) has also been under
development. Unlike the other models, it is a silicone,
pressure-sensitive capacitor that is implanted in the pulmo-
nary artery via right heart catheterization. It is powered
externally by an antenna that is placed on the back or side of
the patient when readings are conducted, and it provides
accurate pulmonary artery pressure assessment when compared
with both Swan-Ganz catheterization and echocardiography
(47). A study of its safety and efficacy, the CHAMPION
(CardioMEMS Heart Sensor Allows Monitoring of Pressure
to Improve Outcomes in NYHA III Heart Failure Patients)
(48), demonstrated that the device can reduce HF hospitaliza-
tions by 30% (95% confidence interval: 0.60 to 0.84) among
NYHA functional class III patients with a HF hospitalization
in the previous 12 months (Online Appendix). Importantly,
clinicians participating in the study were provided with specific
recommendations and guidance on how to adjust HF therapies
on the basis of the hemodynamic readings. Advantages of this
device over other implantable hemodynamic monitors include
its straightforward implantation through right heart catheter-
ization, wireless nature of the sensor, and absence of an
implanted battery requiring subsequent change-out (49). No-
tably, the benefits of sensor-guided treatment were similar in
patients with preserved left ventricular ejection fraction
(LVEF) as those with reduced LVEF, making this system one
of the few management approaches ever demonstrated to
improve outcomes in patients with HF and preserved LVEF.
Additional advantages of implantable devices include the
ability to track measures longitudinally over time, average
these values over the course of a day, and more accurately
reflect a patient’s clinical status. Changes could be compared
with the patient’s own baseline. Such devices also reduce the
need for patient compliance, as measurements are obtained
automatically. Similar to patients with diabetes who can
self-regulate their prescribed therapy based on an objective
daily measurement on their glucometer, the greater poten-
tial in this technology lies in empowering the patient with a
tool to self-monitor and self-manage, particularly if custom-
ized alerts and instructions are given for each patient on the
basis of readings (Fig. 2) (42).
Future Challenges and Opportunities
The field of HF home monitoring has many additional
avenues to investigate (Table 2). Further studies to identify
which patient population will derive the greatest benefit
from home monitoring are needed. Also, identifying which
variables are best to monitor requires further study, whether
it be patient symptoms, directly recorded data such as heart
rate, blood pressure, or pulmonary artery pressures, or
calculated measurements such as intrathoracic impedance
(Table 1). Alternately, monitoring patient behaviors such as
medication adherence may be more important. There are
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taken and even pills with an edible sensor that trigger a
signal when digested (Raisin System, Proteus Biomedical,
Inc., Redwood, California). Home testing and monitoring
of biomarkers may also be of value. Use of serial natriuretic
peptides has been found to be potentially useful in guiding
care of HF patients in some but not all studies in the
outpatient setting, with a meta-analysis of these trials
suggesting that all-cause mortality may be reduced, partic-
ularly in patients younger than 75 years, without clear
reduction in all-cause hospitalization (50). Home testing of
these or other biomarkers should be further explored. As an
increasing amount of information is gathered, however, one
Figure 2 Home Hemodynamic Monitoring of Chronic HF
Changes in therapy can potentially be made more rapidly in response to wirelessly
alerts can be sent to a clinician for review or personalized treatment recommenda
HF  heart failure.
Future Challenges and Opportunities inHome Hemodynamic Monit ingTable 2 Future Challenges and Opportunities inHome Hemodynamic Monitoring
Evaluate in broader patient populations
Evaluate in more diverse clinical settings with more diverse clinicians
managing patients
Better define optimal patient population for monitoring
Further define optimal sensor placement location
Further refine hemodynamic goals
Further study long-term reliability and safety
Evaluate direct patient use of hemodynamic data for self-management
Further analyze cost-effectivenessEvolve reimbursement and professional liability standardsruns the risk of obtaining too much data to manage.
Important alerts may get lost if an appropriate triage system
is not in place.
Any successful approach will likely need to be multi-
pronged. Monitoring alone, without adequate follow-up
and feedback to the patient, is unlikely to be the solution
that prevents HF readmissions or decompensation. Impor-
tantly, as many of the interventions, particularly the im-
planted hemodynamic monitoring devices, were tested in a
select cohort of patients being followed up by experienced
centers, additional study will be needed to determine
whether the benefits can be generalized to a broader cohort
of patients and more diverse group of clinicians and clinical
practice settings. Although these strategies are developed to
reduce the HF burden for the patient and society, these
interventions themselves may also be costly. The ability to
reimburse not only for the devices, but also for the training
and education of patients and staff, will dictate how these
interventions develop. Although chronic care management
programs are potentially cost saving, the benefits from
improved disease control and reduced hospitalization rates
often accrue to the insurers rather than the ambulatory care
practices responsible for providing that care. How these
home monitoring programs are incorporated into the
patient–provider relationship is also a work in progress.
ted hemodynamic data. Even before symptoms develop, data are collected and
an be automatically generated on the basis of a prespecified algorithm.collec
tions cThis prospect will require methods to ensure more effective
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information, and integration into an already busy workflow.
Conclusions
Given the considerable, and largely unmitigated, burden of
HF, the potential for home monitoring to improve the
management of patients with HF is substantial. Home
monitoring of the patient with HF can extend from home
visitations and promotion of self-care to telemedicine and
remote monitoring of external or implantable devices. The
advancement of technology has allowed for the development
of more advanced home-monitoring techniques, including
implanted hemodynamic sensors, which are particularly
promising. In patients with NYHA functional class III HF,
a wireless implanted hemodynamic monitoring system has
now been demonstrated to improve health status and reduce
HF hospitalizations. Whether home-monitoring ap-
proaches for HF will live up to their full potential of
improving quality of life, functional status, and HF out-
comes while reducing healthcare expenditures in the broad
population of patients with HF remains to be seen.
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APPENDIX
For a supplementary table listing the relevant studies of home monitoring,
please see the online version of this article.
